Factor XIa Inhibitor Shows No Benefit After Acute Coronary Syndrome
Investigación reciente An investigational factor XIa inhibitor did not reduce the risk of recurrent cardiovascular (CV) events in patients with a recent acute coronary syndrome (ACS) event on top of antiplatelet therapy, although there was no increase in the risk for major bleeding with treatment, according to the LIBREXIA ACS trial. The phase III results […]
Rush to PCSK9 Inhibitor Pretreatment Disappoints in Acute MI Trial
Resumen del estudio Los pacientes con infarto de miocardio (MI) lograron un control más rápido del colesterol LDL al iniciar la terapia con inhibidores de PCSK9 inmediatamente en el laboratorio de cateterismo según el estudio AMUNDSEN, aunque no se pudo demostrar un beneficio clínico. Los pacientes de alto riesgo con MI agudo que recibieron una […]
Idaho Law Protects Faith Healers. It Wasn’t Always That Way.
Contexto de la ley en Idaho En Idaho, los padres que afirman que su fe prohíbe la atención médica salvavidas para sus hijos no pueden ser acusados de negligencia infantil o homicidio involuntario. A lo largo de los años, los defensores de esta protección han incluido a legisladores que expresaron apoyo por los “valores tradicionales” […]
Statins Handed a Victory in Healthy Older People in STAREE
For the first time, a major randomized trial was able to show that primary prevention statins did have a place for healthy older adults. Study Findings Statin therapy with daily atorvastatin 40 mg was clearly favored over placebo in people 70 and older when tallying the composite of death from cardiovascular causes, nonfatal myocardial infarction […]
First-in-Class Drug Wins FDA Approval for Polycythemia Vera
Aprobación de nuevo fármaco La FDA ha aprobado el primer fármaco de su clase, rusfertide (Mimrylo), para el tratamiento de la eritrocitosis en adultos con policitemia vera (PV), un trastorno hematológico raro y de crecimiento lento. Mecanismo de acción del fármaco Rusfertide imita la hepcidina, la hormona natural involucrada en la regulación de la homeostasis […]
AI predicts hip fracture risk based on EHR
Clinical takeaway: Hip fracture risk may soon be predictable before the first fracture, without adding clinic workload. Identifying who will break a hip is one of the more consequential unsolved problems in preventive care. Hip fractures carry high rates of disability, loss of independence, and death in older adults, and effective preventive measures exist, from […]
Trump’s Weight; Fauci Gets a Legal Defense Fund; Eye Drops Recalled
Nota sobre enlaces Note that some links may require registration or subscription. Preocupaciones sobre el peso de Trump Doctors shared concerns as President Trump appears to have put on 23 pounds since his 2024 campaign. (Washington Post) Corrigiendo información sobre vacunas CMS Administrator Mehmet Oz, MD, corrected Trump and said the measles, mumps, and rubella […]
Controversial Neurologist to Lead NIH Unit; Hunter Trial Halted; Dads and Valproate
New Leadership at NIH The NIH has appointed Dr. John Gaitanis, a pediatric neurologist known for his controversial views on autism, to lead its child health institute. This appointment has garnered significant attention due to the ongoing debates surrounding autism research. Menopause and Brain Health A recent cohort study has indicated a correlation between age […]
HHS Call for Input May Shed Light on Trump Administration’s Vaccine Plans
In the wake of a controversial executive orderopens in a new tab or window that shrinks the number of universally recommended vaccines for children, HHS is asking the public to weigh in onopens in a new tab or window whether three categories used in federal vaccine recommendations are adequate. The three categories up for discussion […]
Dementia Drug Helpful With Lupus Brain Fog
Resumen del estudio Cognitive dysfunction in people with systemic lupus erythematosus (SLE) — aka “lupus brain fog” — was significantly relieved with the Alzheimer’s dementia drug memantine in a small placebo-controlled trial. Twelve weeks of memantine treatment led to a median improvement of 8 points on the Repeatable Battery for the Assessment of Neuropsychological Status […]